Reported 8 months ago
Taiwan FDA Director Wu Hsiu-mei estimates that the supply situation will not stabilize until October at the earliest. The major IV bag manufacturer with a market share of 70%, Yung-Feng Chemical Industry Co., Ltd., has halted production due to significant violations. In response, the Taiwan Ministry of Health and Welfare has implemented a dual strategy of increasing domestic production and importing special projects, with around 880,000 bags imported and 240,000 domestically produced so far. Director Wu stated that the weekly usage is 300,000 bags, and while there are no shortages at the user end, the main impact is on internal inventory levels. To meet clinical demands, domestic manufacturers are ramping up production, and as of this week, a total of 680,000 bags have been distributed to 174 healthcare institutions, combining both domestically produced and specially imported bags. The current deliveries include bags from Greece, Japan, Indonesia, and more. The Taiwan FDA has also established a platform for alternative drug information and matching mechanisms for medical institutions facing procurement difficulties, successfully mediating 724 cases reported by 359 hospitals and clinics as of June 18, 2024.
Source: YAHOO